Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Original Article

Volume 7, Number 3, September 2018, pages 96-106

Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy

Figures

Figure 1.
Figure 1. Cytokine synthesis by PMA-activated CD4+ve T cells from chronic phase CML (CP CM) patients pre-Imatinib therapy compared with normal controls and patients with resistance to Imatinib therapy (IM Res CML). Data are presented as mean percentages ± SEM. Data are presented as mean percentages ± SEM. a (IFN-ã), c (TNF-á) and e (IL-4) represent data for CP CM patients regardless of their response to therapy, while b (IFN-ã), d (TNF-á) and f (IL-4) represent data CP CM patients grouped according to their response to IM therapy. OR: optimal response; nOR: no optimal response.
Figure 2.
Figure 2. Cytokine synthesis by PMA-activated CD8+ve T cells from chronic phase CML (CP CML) patients pre-Imatinib therapy compared with normal controls and patients with resistance to Imatinib therapy (IM Res CML). Data are presented as mean percentages ± SEM. a (IFN-ã), c (TNF-á) and e (IL-4) represent data for CP CML patients regardless of their response to therapy, while b (IFN-ã), d (TNF-á) and f (IL-4) represent data CP CML patients grouped according to their response to IM therapy. OR: optimal response; nOR: no optimal response.
Figure 3.
Figure 3. Mean percentages of IFN-ã (a and b), TNF-á (c and d) and IL-4 (e and f), synthesized by CD4+ve and CD8+ve T cells of chronic phase CML patients with optimal response (CML OR) pre- and during Imatinib therapy (6 weeks, 3 months, 6 months and 9 months) compared with normal controls and CML patients known to have Imatinib resistance (CML IM Res).

Table

Table 1. Characteristics of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients Included in the Study
 
PatientSexAgePhaseWBC (×109/L)Hb (g/dL)Plt (×109/L)Initial therapyKaryotype
WBC: white blood cell; Hb: hemoglobin; Plt: platelet count.
1M42CP18212.1822Hydroxyureat(9:22)
2M26CP17911.1784Hydroxyureat(9:22)
3M38CP8010.8586Hydroxyureat(9:22)
4M26CP22212.1642Hydroxyureat(9:22)
5M44CP288.961,394Hydroxyureat(6:9:22)
6M34CP4210.4567Hydroxyureat(9:22)
7F53CP4418415Hydroxyureat(9:22)
8M32CP1857653Hydroxyureat(9:22)
9M37CP8511818Hydroxyureat(9:22)
10F70CP108101,034Hydroxyureat(9:22)
11F47CP173Hydroxyureat(9:22)
12M33CP20012145Hydroxyureat(9:22)
13F26CP33191,162Hydroxyureat(9:22)
14M37CP24291,034Hydroxyureat(9:22)
15F44CP1539335Hydroxyureat(9:22)
16F57CP6414335Hydroxyureat(9:22)
17F57CP19614640Hydroxyureat(9:22)
18M32CP6387115Hydroxyureat(9:22)
19M30CP10613868Hydroxyureat(9:22)
20Fe34CP2677399Hydroxyureat(9:22)